A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
S1507 is closed to accrual effective March 15, 2018, at 11:59 p.m. Pacific.
